MLAB
Mesa Laboratories, Inc.
Price Chart
Latest Quote
$94.45
+2.48 (+2.70%)
Current Price
| Previous Close | $91.97 |
| Open | $91.98 |
| Day High | $96.55 |
| Day Low | $91.96 |
| Volume | 179,863 |
Stock Information
| Quarterly Dividend / Yield | $0.64 / 0.70% |
| Shares Outstanding | 5.52M |
| Quarterly Dividend Yield | 0.70% |
| Quarterly Dividend | $0.64 |
| Total Debt | $168.83M |
| Cash Equivalents | $28.57M |
| Revenue | $249.13M |
| Net Income | $6.71M |
| Sector | Technology |
| Industry | Scientific & Technical Instruments |
| Market Cap | $521.83M |
| P/E Ratio | 78.06 |
| EPS (TTM) | $1.21 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $648.39M |
| Sales | $249.13M |
| Income | $6.71M |
| Book/sh | $33.71 |
| Cash/sh | $5.17 |
| Employees | 717 |
Financial Ratios
| Quick Ratio | 1.17 |
| Current Ratio | 1.72 |
| Debt/Eq | 90.65 |
Returns & Margins
| ROA | 2.69% |
| ROE | 3.88% |
| Gross Margin | 63.53% |
| Operating Margin | 4.31% |
| Profit Margin | 2.69% |
Ownership
| Insider Ownership | 5.63% |
| Institutional Ownership | 93.85% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 7.70 |
| P/S | 2.09 |
| P/B | 2.80 |
Analyst Data
| Recommendation | none |
| Target Price | $112.00 |
Technical Indicators
| SMA20 | $101.80 |
| SMA50 | $101.75 |
| SMA200 | $85.18 |
| RSI | 35.91 |
| ATR | 5.7900 |
| Shares Float | 4.94M |
| Short Float | 7.38% |
| Short Ratio | 1.65 |
| Volatility | 0.93 |
| Rel Volume | 0.70 |
Performance History
| Week | -5.25% |
| Month | -12.93% |
| Quarter | +16.60% |
| 6 Months | +16.92% |
| YTD | +19.29% |
| Year | -2.80% |
| 3 Years | -29.00% |
| 5 Years | -62.03% |
| 10 Years | -17.31% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $94.45 | 179,863 |
| 2026-06-23 | $91.97 | 208,500 |
| 2026-06-22 | $93.23 | 208,800 |
| 2026-06-18 | $95.10 | 174,300 |
| 2026-06-17 | $94.95 | 272,500 |
| 2026-06-16 | $99.68 | 260,900 |
| 2026-06-15 | $104.08 | 559,000 |
| 2026-06-12 | $105.48 | 395,600 |
| 2026-06-11 | $107.35 | 239,500 |
| 2026-06-10 | $107.22 | 273,200 |
| 2026-06-09 | $109.03 | 362,700 |
| 2026-06-08 | $108.46 | 181,400 |
| 2026-06-05 | $103.89 | 218,100 |
| 2026-06-04 | $109.13 | 135,400 |
| 2026-06-03 | $104.38 | 138,300 |
| 2026-06-02 | $106.66 | 229,200 |
| 2026-06-01 | $105.26 | 230,900 |
| 2026-05-29 | $102.02 | 286,400 |
| 2026-05-28 | $102.94 | 225,300 |
| 2026-05-27 | $90.66 | 352,700 |
| 2026-05-26 | $106.01 | 266,100 |
About Mesa Laboratories, Inc.
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.
đ° Latest News
Mesa Laboratories: Priced for the Problem, Not the Platform
GuruFocus.com âĸ 2026-06-17T08:42:30Z3 Stocks Estimated To Be Trading 16.4% To 42% Below Intrinsic Value
Simply Wall St. âĸ 2026-06-04T17:38:22Z
Why Mesa Laboratories Stock Is Getting Hit With a Huge Sell-Off Today
Motley Fool âĸ 2026-05-27T19:56:19Z
Undervalued Small Caps With Insider Buying Across Regions
Simply Wall St. âĸ 2026-05-22T11:39:46Z
Undervalued Small Caps With Insider Buying Across Regions To Consider
Simply Wall St. âĸ 2026-04-20T11:39:51Z
Hereâs Why Conestoga Capital Advisors Sold Mesa Laboratories (MLAB)
Insider Monkey âĸ 2026-02-20T12:02:34Z
Mesa Laboratories, Inc.'s (NASDAQ:MLAB) Stock Going Strong But Fundamentals Look Weak: What Implications Could This Have On The Stock?
Simply Wall St. âĸ 2026-02-05T10:17:31Z
Mesa Labs: Fiscal Q3 Earnings Snapshot
Associated Press Finance âĸ 2026-02-03T13:11:43ZMesa Laboratories' (NASDAQ:MLAB) Dividend Will Be $0.16
Simply Wall St. âĸ 2026-01-11T12:17:31Z
Should You Investigate Mesa Laboratories, Inc. (NASDAQ:MLAB) At US$77.63?
Simply Wall St. âĸ 2025-12-07T13:24:05Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $90,860,000 | $90,108,000 | $82,937,000 | $85,387,000 |
| Cost Of Revenue | $90,860,000 | $90,108,000 | $82,937,000 | $85,387,000 |
| Total Revenue | $249,130,000 | $240,978,000 | $216,187,000 | $219,080,000 |
| Operating Revenue | $249,130,000 | $240,978,000 | $216,187,000 | $219,080,000 |
| Expenses | ||||
| Interest Expense | $10,692,000 | $11,859,000 | $5,697,000 | $4,770,000 |
| Total Expenses | $230,619,000 | $224,642,000 | $213,729,000 | $215,760,000 |
| Other Income Expense | $4,195,000 | $1,484,000 | $-272,409,000 | $1,061,000 |
| Other Non Operating Income Expenses | $4,195,000 | $-1,403,000 | $2,124,000 | $1,061,000 |
| Net Non Operating Interest Income Expense | $-10,692,000 | $-11,859,000 | $-5,697,000 | $-4,770,000 |
| Interest Expense Non Operating | $10,692,000 | $11,859,000 | $5,697,000 | $4,770,000 |
| Operating Expense | $139,759,000 | $134,534,000 | $130,792,000 | $130,373,000 |
| Selling And Marketing Expense | $40,793,000 | $41,683,000 | $38,625,000 | $37,439,000 |
| General And Administrative Expense | $78,658,000 | $73,333,000 | $72,867,000 | $72,444,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $6,712,000 | $-1,974,000 | $-254,246,000 | $930,000 |
| Net Interest Income | $-10,692,000 | $-11,859,000 | $-5,697,000 | $-4,770,000 |
| Normalized Income | $6,712,000 | $-4,254,730 | $-1,028,429 | $930,000 |
| Net Income From Continuing And Discontinued Operation | $6,712,000 | $-1,974,000 | $-254,246,000 | $930,000 |
| Total Operating Income As Reported | $18,511,000 | $16,336,000 | $-272,075,000 | $3,320,000 |
| Net Income Common Stockholders | $6,712,000 | $-1,974,000 | $-254,246,000 | $930,000 |
| Net Income | $6,712,000 | $-1,974,000 | $-254,246,000 | $930,000 |
| Net Income Including Noncontrolling Interests | $6,712,000 | $-1,974,000 | $-254,246,000 | $930,000 |
| Net Income Continuous Operations | $6,712,000 | $-1,974,000 | $-254,246,000 | $930,000 |
| Pretax Income | $12,014,000 | $5,961,000 | $-275,648,000 | $-389,000 |
| Special Income Charges | $0 | $2,887,000 | $-274,533,000 | $0 |
| Operating Income | $18,511,000 | $16,336,000 | $2,458,000 | $3,320,000 |
| Gross Profit | $158,270,000 | $150,870,000 | $133,250,000 | $133,693,000 |
| Interest Income | - | - | - | - |
| Interest Income Non Operating | - | - | - | - |
| Per Share | ||||
| Diluted EPS | - | $-0.36 | $-47.20 | $0.17 |
| Basic EPS | - | $-0.36 | $-47.20 | $0.17 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $606,270 | $-21,315,429 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $45,977,000 | $39,460,000 | $36,156,000 | $37,515,000 |
| Total Unusual Items | $0 | $2,887,000 | $-274,533,000 | $0 |
| Total Unusual Items Excluding Goodwill | $0 | $2,887,000 | $-274,533,000 | $0 |
| Reconciled Depreciation | $23,271,000 | $24,527,000 | $31,574,000 | $33,134,000 |
| EBITDA (Bullshit earnings) | $45,977,000 | $42,347,000 | $-238,377,000 | $37,515,000 |
| EBIT | $22,706,000 | $17,820,000 | $-269,951,000 | $4,381,000 |
| Diluted NI Availto Com Stockholders | $6,712,000 | $-1,974,000 | $-254,246,000 | $930,000 |
| Tax Provision | $5,302,000 | $7,935,000 | $-21,402,000 | $-1,319,000 |
| Impairment Of Capital Assets | $0 | $0 | $274,533,000 | $0 |
| Research And Development | $20,308,000 | $19,518,000 | $19,300,000 | $20,490,000 |
| Selling General And Administration | $119,451,000 | $115,016,000 | $111,492,000 | $109,883,000 |
| Other Gand A | $78,658,000 | $73,333,000 | $72,867,000 | $72,444,000 |
| Diluted Average Shares | - | $5,421,000 | $5,386,000 | $5,361,000 |
| Basic Average Shares | - | $5,421,000 | $5,386,000 | $5,321,000 |
| Other Special Charges | - | $-2,887,000 | - | - |
Fetched: 2026-06-23
Balance Sheet (Annual)
| Metric | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-83,965,000 | $-118,805,000 | $-148,455,000 | $-109,779,000 |
| Total Assets | $427,747,000 | $433,348,000 | $446,796,000 | $661,832,000 |
| Total Non Current Assets | $321,479,000 | $330,663,000 | $337,444,000 | $542,857,000 |
| Other Non Current Assets | $19,155,000 | $18,324,000 | $10,538,000 | $10,373,000 |
| Non Current Deferred Assets | $1,501,000 | $1,371,000 | $1,292,000 | $1,076,000 |
| Non Current Deferred Taxes Assets | $1,501,000 | $1,371,000 | $1,292,000 | $1,076,000 |
| Goodwill And Other Intangible Assets | $270,210,000 | $278,635,000 | $293,848,000 | $503,259,000 |
| Other Intangible Assets | $83,347,000 | $96,875,000 | $113,752,000 | $216,815,000 |
| Current Assets | $106,268,000 | $102,685,000 | $109,352,000 | $118,975,000 |
| Other Current Assets | $3,620,000 | $2,873,000 | $3,341,000 | $4,045,000 |
| Prepaid Assets | $5,248,000 | $5,156,000 | $6,067,000 | $4,827,000 |
| Inventory | $26,373,000 | $25,365,000 | $32,675,000 | $34,642,000 |
| Receivables | $44,099,000 | $41,970,000 | $39,055,000 | $42,551,000 |
| Accounts Receivable | $44,099,000 | $41,970,000 | $39,055,000 | $42,551,000 |
| Allowance For Doubtful Accounts Receivable | $-2,569,000 | $-1,186,000 | $-1,321,000 | $-849,000 |
| Gross Accounts Receivable | $46,668,000 | $43,156,000 | $40,376,000 | $43,400,000 |
| Cash Cash Equivalents And Short Term Investments | $26,928,000 | $27,321,000 | $28,214,000 | $32,910,000 |
| Cash And Cash Equivalents | $26,928,000 | $27,321,000 | $28,214,000 | $32,910,000 |
| Debt | ||||
| Net Debt | $124,554,000 | $150,628,000 | $193,484,000 | $150,362,000 |
| Total Debt | $155,169,000 | $181,472,000 | $224,684,000 | $186,140,000 |
| Long Term Debt And Capital Lease Obligation | $145,857,000 | $76,902,000 | $221,698,000 | $183,272,000 |
| Long Term Debt | $145,857,000 | $76,902,000 | $221,698,000 | $183,272,000 |
| Current Debt And Capital Lease Obligation | $9,312,000 | $104,570,000 | $2,986,000 | $2,868,000 |
| Current Debt | $5,625,000 | $101,047,000 | - | - |
| Other Current Borrowings | $5,625,000 | $101,047,000 | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $241,502,000 | $273,518,000 | $301,403,000 | $268,352,000 |
| Total Non Current Liabilities Net Minority Interest | $179,604,000 | $109,555,000 | $257,091,000 | $224,993,000 |
| Other Non Current Liabilities | $13,662,000 | $12,472,000 | $15,613,000 | $7,693,000 |
| Non Current Deferred Liabilities | $20,085,000 | $20,181,000 | $19,780,000 | $34,028,000 |
| Non Current Deferred Taxes Liabilities | $20,085,000 | $20,181,000 | $19,780,000 | $34,028,000 |
| Current Liabilities | $61,898,000 | $163,963,000 | $44,312,000 | $43,359,000 |
| Current Deferred Liabilities | $14,723,000 | $14,710,000 | $15,478,000 | $15,694,000 |
| Payables And Accrued Expenses | $37,863,000 | $44,683,000 | $25,848,000 | $24,797,000 |
| Payables | $35,629,000 | $31,758,000 | $23,148,000 | $22,500,000 |
| Other Payable | $16,689,000 | $15,383,000 | $7,979,000 | $7,451,000 |
| Total Tax Payable | $14,012,000 | $10,628,000 | $9,128,000 | $8,915,000 |
| Income Tax Payable | $4,745,000 | $2,157,000 | $1,615,000 | $992,000 |
| Accounts Payable | $4,928,000 | $5,747,000 | $6,041,000 | $6,134,000 |
| Interest Payable | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $186,245,000 | $159,830,000 | $145,393,000 | $393,480,000 |
| Total Equity Gross Minority Interest | $186,245,000 | $159,830,000 | $145,393,000 | $393,480,000 |
| Stockholders Equity | $186,245,000 | $159,830,000 | $145,393,000 | $393,480,000 |
| Gains Losses Not Affecting Retained Earnings | $-3,356,000 | $-9,775,000 | $-14,755,000 | $-12,795,000 |
| Other Equity Adjustments | $-3,356,000 | $-9,775,000 | $-14,755,000 | $-12,795,000 |
| Retained Earnings | $-185,747,000 | $-188,936,000 | $-183,494,000 | $74,199,000 |
| Other | ||||
| Ordinary Shares Number | $5,524,931 | $5,455,421 | $5,394,491 | $5,369,466 |
| Share Issued | $5,524,931 | $5,455,421 | $5,394,491 | $5,369,466 |
| Tangible Book Value | $-83,965,000 | $-118,805,000 | $-148,455,000 | $-109,779,000 |
| Invested Capital | $337,727,000 | $337,779,000 | $367,091,000 | $576,752,000 |
| Working Capital | $44,370,000 | $-61,278,000 | $65,040,000 | $75,616,000 |
| Capital Lease Obligations | $3,687,000 | $3,523,000 | $2,986,000 | $2,868,000 |
| Total Capitalization | $332,102,000 | $236,732,000 | $367,091,000 | $576,752,000 |
| Capital Stock | $375,348,000 | $358,541,000 | $343,642,000 | $332,076,000 |
| Common Stock | $375,348,000 | $358,541,000 | $343,642,000 | $332,076,000 |
| Current Deferred Revenue | $14,723,000 | $14,710,000 | $15,478,000 | $15,694,000 |
| Current Capital Lease Obligation | $3,687,000 | $3,523,000 | $2,986,000 | $2,868,000 |
| Current Accrued Expenses | $2,234,000 | $12,925,000 | $2,700,000 | $2,297,000 |
| Goodwill | $186,863,000 | $181,760,000 | $180,096,000 | $286,444,000 |
| Net PPE | $30,613,000 | $32,333,000 | $31,766,000 | $28,149,000 |
| Accumulated Depreciation | $-30,115,000 | $-26,421,000 | $-22,519,000 | $-19,768,000 |
| Gross PPE | $60,728,000 | $58,754,000 | $54,285,000 | $47,917,000 |
| Construction In Progress | $1,467,000 | $1,610,000 | $1,380,000 | $1,735,000 |
| Other Properties | $31,346,000 | $29,882,000 | $24,923,000 | $18,875,000 |
| Machinery Furniture Equipment | $3,658,000 | $3,093,000 | $3,613,000 | $4,413,000 |
| Buildings And Improvements | $23,368,000 | $23,280,000 | $23,480,000 | $22,005,000 |
| Land And Improvements | $889,000 | $889,000 | $889,000 | $889,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $10,575,000 | $10,030,000 | $13,084,000 | $13,961,000 |
| Work In Process | $925,000 | $560,000 | $1,256,000 | $617,000 |
| Raw Materials | $14,873,000 | $14,775,000 | $18,335,000 | $20,064,000 |
| Treasury Shares Number | - | - | $0 | - |
Fetched: 2026-06-23
Cash Flow Statement (Annual)
| Metric | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $39,581,000 | $42,309,000 | $41,566,000 | $23,439,000 |
| Operating Activities | ||||
| Operating Cash Flow | $42,831,000 | $46,808,000 | $44,133,000 | $27,983,000 |
| Cash Flow From Continuing Operating Activities | $42,831,000 | $46,808,000 | $44,133,000 | $27,983,000 |
| Operating Gains Losses | - | $-2,887,000 | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-3,250,000 | $-4,499,000 | $-2,567,000 | $-4,544,000 |
| Investing Cash Flow | $-3,250,000 | $-4,499,000 | $-81,306,000 | $-9,494,000 |
| Cash Flow From Continuing Investing Activities | $-3,250,000 | $-4,499,000 | $-81,306,000 | $-9,494,000 |
| Financing Activities | ||||
| Financing Cash Flow | $-41,854,000 | $-44,509,000 | $32,836,000 | $-33,328,000 |
| Cash Flow From Continuing Financing Activities | $-41,854,000 | $-44,509,000 | $32,836,000 | $-33,328,000 |
| Net Other Financing Charges | $-11,582,000 | $-1,339,000 | $-1,575,000 | $-919,000 |
| Cash Dividends Paid | $-3,523,000 | $-3,468,000 | $-3,447,000 | $-3,406,000 |
| Common Stock Dividend Paid | $-3,523,000 | $-3,468,000 | $-3,447,000 | $-3,406,000 |
| Issuance Of Capital Stock | - | - | - | $0 |
| Net Common Stock Issuance | - | - | - | $0 |
| Common Stock Issuance | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $-134,249,000 | $-115,811,000 | $-33,500,000 | $-36,000,000 |
| Issuance Of Debt | $107,500,000 | $73,465,000 | $71,000,000 | $0 |
| Interest Paid Supplemental Data | $10,017,000 | $11,077,000 | $4,648,000 | $3,485,000 |
| Income Tax Paid Supplemental Data | $1,870,000 | $5,731,000 | $4,591,000 | $1,356,000 |
| End Cash Position | $26,928,000 | $27,321,000 | $28,214,000 | $32,910,000 |
| Beginning Cash Position | $27,321,000 | $28,214,000 | $32,910,000 | $49,346,000 |
| Effect Of Exchange Rate Changes | $1,880,000 | $1,307,000 | $-359,000 | $-1,597,000 |
| Changes In Cash | $-2,273,000 | $-2,200,000 | $-4,337,000 | $-14,839,000 |
| Proceeds From Stock Option Exercised | $0 | $2,644,000 | $358,000 | $6,997,000 |
| Net Issuance Payments Of Debt | $-26,749,000 | $-42,346,000 | $37,500,000 | $-36,000,000 |
| Net Long Term Debt Issuance | $-26,749,000 | $-42,346,000 | $37,500,000 | $-36,000,000 |
| Long Term Debt Payments | $-134,249,000 | $-115,811,000 | $-33,500,000 | $-36,000,000 |
| Long Term Debt Issuance | $107,500,000 | $73,465,000 | $71,000,000 | $0 |
| Net Business Purchase And Sale | $0 | $0 | $-78,739,000 | $-4,950,000 |
| Purchase Of Business | $0 | $0 | $-78,739,000 | $-4,950,000 |
| Net Intangibles Purchase And Sale | $0 | $-250,000 | $0 | $0 |
| Purchase Of Intangibles | $0 | $-250,000 | $0 | $0 |
| Net PPE Purchase And Sale | $-3,250,000 | $-4,249,000 | $-2,567,000 | $-4,544,000 |
| Purchase Of PPE | $-3,250,000 | $-4,249,000 | $-2,567,000 | $-4,544,000 |
| Change In Working Capital | $-4,987,000 | $6,904,000 | $5,973,000 | $-17,112,000 |
| Change In Other Working Capital | $-255,000 | $-938,000 | $-408,000 | $606,000 |
| Change In Payables And Accrued Expense | $2,300,000 | $9,116,000 | $-1,333,000 | $-4,905,000 |
| Change In Accrued Expense | $3,497,000 | $9,504,000 | $-1,236,000 | $-3,360,000 |
| Change In Payable | $-1,197,000 | $-388,000 | $-97,000 | $-1,545,000 |
| Change In Account Payable | $-1,197,000 | $-388,000 | $-97,000 | $-1,545,000 |
| Change In Prepaid Assets | $608,000 | $498,000 | $211,000 | $-510,000 |
| Change In Inventory | $-4,434,000 | $1,153,000 | $2,563,000 | $-10,182,000 |
| Change In Receivables | $-3,206,000 | $-2,925,000 | $4,940,000 | $-2,121,000 |
| Changes In Account Receivables | $-3,206,000 | $-2,925,000 | $4,940,000 | $-2,121,000 |
| Other Non Cash Items | $1,259,000 | $7,168,000 | $2,784,000 | $1,987,000 |
| Stock Based Compensation | $17,868,000 | $13,142,000 | $11,936,000 | $12,538,000 |
| Asset Impairment Charge | $0 | $0 | $274,533,000 | $0 |
| Deferred Tax | $-1,292,000 | $-72,000 | $-28,421,000 | $-3,494,000 |
| Deferred Income Tax | $-1,292,000 | $-72,000 | $-28,421,000 | $-3,494,000 |
| Depreciation Amortization Depletion | $23,271,000 | $24,527,000 | $31,574,000 | $33,134,000 |
| Depreciation And Amortization | $23,271,000 | $24,527,000 | $31,574,000 | $33,134,000 |
| Amortization Cash Flow | $18,017,000 | $19,145,000 | $27,341,000 | $28,821,000 |
| Amortization Of Intangibles | $18,017,000 | $19,145,000 | $27,341,000 | $28,821,000 |
| Depreciation | $5,254,000 | $5,382,000 | $4,233,000 | $4,313,000 |
| Net Income From Continuing Operations | $6,712,000 | $-1,974,000 | $-254,246,000 | $930,000 |
Fetched: 2026-06-23